Semble funding, valuation and investors

Overview

Semble is a London-based healthtech company founded in 2016 by Mikael Landau and Christoph Lippuner. Its cloud platform combines electronic health records, scheduling, billing, patient communications, e-prescriptions, and telehealth for private outpatient clinics across 80+ specialties. Semble Connect integrates with 1,200+ external tools (CRM, labs, diagnostics, HR) and serves 1,700+ healthcare businesses used daily by 16,000+ clinicians. In June 2026 Semble raised £30 million Series C led by Revaia with new investor Partech and returning Mercia Ventures and Octopus Ventures, bringing total funding to approximately £57 million. The company operates primarily in the UK and France and is investing in AI-powered care orchestration.

Why Semble is interesting

Semble passed 10M patients on its platform—roughly one in six people in the UK touched a Semble-powered clinician—then raised £30M Series C to become the "system of action" for outpatient care orchestration, not another digital filing cabinet.

Product & use cases

Semble unifies clinical workflows (consultations, records, e-prescribing) with practice operations (booking, invoicing, reminders, payments) in one platform. Enterprise customers use Semble Connect and APIs to automate finance, marketing, and diagnostics integrations without replacing core clinical software.

• Solo GPs and consultants replacing legacy practice-management systems
• Multi-site private clinic groups standardizing scheduling and billing across locations
• Mental health, physio, and specialty practices needing telehealth and patient portals
• Large healthcare enterprises orchestrating care journeys across UK and France

Key facts

• Series C (Jun 2026): £30M led by Revaia; Partech new; Mercia and Octopus return
• 10M+ patients received care via Semble clinicians; 1,700+ healthcare businesses
• 1,200+ integrations via Semble Connect—positioned as Europe's most connected private-health platform
• 16,000+ daily clinical users across 80+ specialties
• Total funding ~£57M after nearly doubling since £11.5M Series B (Oct 2024)
• Subscription pricing from ~£119/user/month per public listings

Funding history (newest first)

Competitive landscape

Edge: Interoperability depth—1,200+ tool connections—and clinical + operational unity versus legacy EHRs that store records without orchestrating the full patient journey.

European private healthcare IT is fragmented; winners need switching costs via integrations and multi-site deployments. Semble's Series C funds expansion among large groups and AI orchestration—competing on connected workflows, not feature checklists alone.

• EMIS / legacy UK EHR vendors incumbent

  Established NHS and private systems; Semble targets modern cloud-native private outpatient providers.

• Hint Health direct

  Direct-primary-care practice software; overlapping private-clinic audience.

• Modernizing Medicine direct

  Specialty-specific cloud EHR; Semble emphasizes cross-specialty platform breadth in Europe.

• Doctolib adjacent

  Booking and practice tools in France; overlaps on scheduling though Semble is broader PM+EHR.

Notable stories

• Semble reported that 10 million UK patients—about one in six—received care from a clinician using its platform at Series C announcement (Semble blog, June 2026).
• Revaia partner Morgan Kessous called Semble the "system of action for modern healthcare," not just storage—a framing the company uses against legacy EHR positioning (Semble press release).

Industries

Related funding articles

Venture Capital Tracker pieces that cover Semble's financing or category context.

• Semble's £30M Series C: Modern Software for Healthcare Providers